Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

PALI

Palisade Bio Inc

May 17 • 04:00PM ET

6.36

Dollar change -0.10
Percentage change -1.55	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-24.71	Insider Own	1.76%	Shs Outstand	0.94M	Perf Week	-5.22%
Market Cap	5.98M	Forward P/E	-	EPS next Y	-14.08	Insider Trans	181.33%	Shs Float	0.92M	Perf Month	25.44%
Income	-13.50M	PEG	-	EPS next Q	-3.11	Inst Own	6.98%	Short Float	19.40%	Perf Quarter	-1.44%
Sales	0.00M	P/S	-	EPS this Y	53.70%	Inst Trans	-	Short Ratio	0.16	Perf Half Y	-20.02%
Book/sh	11.82	P/B	0.54	EPS next Y	-12.64%	ROA	-96.75%	Short Interest	0.18M	Perf Year	-73.66%
Cash/sh	12.00	P/C	0.53	EPS next 5Y	-	ROE	-113.42%	52W Range	3.82 - 36.60	Perf YTD	-28.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	75.28%	ROI	-133.40%	52W High	-82.62%	Beta	1.31
Dividend TTM	-	Quick Ratio	4.84	Sales past 5Y	-38.82%	Gross Margin	78.40%	52W Low	66.49%	ATR (14)	0.87
Dividend Ex-Date	-	Current Ratio	4.84	EPS Y/Y TTM	86.01%	Oper. Margin	0.00%	RSI (14)	49.52	Volatility	9.37% 14.09%
Employees	9	Debt/Eq	0.02	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	22.50
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	43.55%	Payout	-	Rel Volume	0.02	Prev Close	6.46
Sales Surprise	-	EPS Surprise	-22.40%	Sales Q/Q	-100.00%	Earnings	May 14 BMO	Avg Volume	1.14M	Price	6.36
SMA20	-2.81%	SMA50	7.36%	SMA200	-25.05%	Trades		Volume	27,805	Change	-1.55%

May-14-24 08:05AM	Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-13-24 10:53PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q1 2024 (InvestorPlace) -7.30%
May-07-24 08:30AM	Palisade Bio Appoints Margery Fischbein to its Board of Directors (GlobeNewswire) -6.62%
07:30AM	Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
May-02-24 08:30AM	Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules (GlobeNewswire)
08:30AM	Loading…
May-01-24 08:30AM	Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS) (GlobeNewswire) +17.41%
Apr-23-24 08:30AM	Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach (GlobeNewswire) +20.08%
Apr-16-24 11:22AM	Why Is Palisade Bio (PALI) Stock Up 57% Today? (InvestorPlace) +42.55%
08:30AM	Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients' Stool (GlobeNewswire)
Apr-11-24 09:15AM	Palisade Bio to Participate in the Virtual Investor Lunch Break Event (GlobeNewswire) +7.62%
Apr-10-24 08:15AM	Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis (GlobeNewswire) -24.91%
Apr-03-24 05:30PM	Palisade Bio Announces 1-for-15 Reverse Stock Split (GlobeNewswire)
Mar-27-24 08:00AM	Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +6.04%
Mar-26-24 11:52PM	PALI Stock Earnings: Palisade Bio Beats EPS for Q4 2023 (InvestorPlace)
Feb-15-24 08:35AM	Palisade Bio to Present at Digestive Disease Week (DDW) 2024 (GlobeNewswire)
08:35AM	Loading…
Feb-13-24 08:35AM	Palisade Bio Provides Corporate Update and Reiterates Guidance (GlobeNewswire)
Feb-08-24 02:40PM	Correction Notice of Palisade Bio's Press Release Announcing the Appointment of Clinical Advisory Board Members (GlobeNewswire)
08:05AM	Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders (GlobeNewswire)
Jan-30-24 09:25AM	Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million (GlobeNewswire) -35.01%
Jan-29-24 02:01PM	Why Is Palisade Bio (PALI) Stock Up 100% Today? (InvestorPlace) +84.62%
08:05AM	Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress (GlobeNewswire)
Jan-09-24 08:00AM	Palisade Bio Selected for Poster Presentation at the 2024 Crohn's & Colitis Congress (GlobeNewswire)
Dec-29-23 04:52AM	Palisade Bio receives milestone payment for PALI-2108 development (Pharmaceutical Business Review) -9.77%
Dec-28-23 08:00AM	Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn's and Colitis Foundation for Development of PALI-2108 (GlobeNewswire) +8.98%
Nov-10-23 08:05AM	Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook (GlobeNewswire)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE)
Oct-11-23 09:05AM	Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference (GlobeNewswire)
Sep-14-23 07:13PM	Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc (GuruFocus.com)
Sep-11-23 04:01PM	Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules (GlobeNewswire)
08:35AM	Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
08:30AM	Loading…
Sep-07-23 08:30AM	Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules (GlobeNewswire) -45.85%
Sep-06-23 08:45AM	Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease (GlobeNewswire) +108.79%
Aug-11-23 08:05AM	Palisade Bio Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 08:05AM	Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions (GlobeNewswire) -62.70%
Jul-05-23 08:45AM	Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study (GlobeNewswire)
Jun-22-23 08:30AM	PALISADES ANNOUNCES NEW FOUND MAKES NEW HIGH-GRADE, AT SURFACE DISCOVERY AT JACKPOT ZONE AT QUEENSWAY PROJECT (PR Newswire)
Jun-14-23 08:45AM	Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Jun-01-23 08:45AM	Palisade Bio Promotes J.D. Finley to Chief Executive Officer (GlobeNewswire) +9.09%
May-24-23 08:45AM	Palisade Bios LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts (GlobeNewswire) -7.64%
May-17-23 08:30AM	PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT KEATS WEST (PR Newswire)
May-12-23 08:05AM	Palisade Bio Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-11-23 09:05AM	Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study (GlobeNewswire)
Apr-06-23 09:00AM	Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148 (GlobeNewswire)
Apr-05-23 08:35AM	Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148 (GlobeNewswire) +7.39%
Apr-04-23 08:30AM	PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT ICEBERG (PR Newswire) -10.18%
Apr-03-23 08:30AM	Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) -35.80%
Mar-23-23 08:05AM	Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-15-23 08:30AM	PALISADES ANNOUNCES NEW FOUND'S INCREASED WEIGHTING BY GDXJ (PR Newswire) -6.60%
Mar-01-23 09:05AM	Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent (GlobeNewswire)
Feb-08-23 08:35AM	Palisade Bio Promotes Robert McRae to Chief Operating Officer (GlobeNewswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-10-23 08:35AM	Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million (GlobeNewswire)
Jan-09-23 08:45AM	Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire)
Jan-04-23 05:15PM	Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) +6.02%
Dec-30-22 08:45AM	Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) +61.49%
Dec-16-22 08:05AM	Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions (GlobeNewswire)
Dec-07-22 08:35AM	Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million (GlobeNewswire) -6.81%
Dec-01-22 02:44PM	Palisade Bio Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-22-22 08:35AM	Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery (GlobeNewswire) +81.90%
Nov-18-22 08:05AM	Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer (GlobeNewswire) -7.89%
Nov-17-22 08:30AM	Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video (GlobeNewswire) -5.67%
Nov-15-22 11:15AM	Palisade Bio Announces Reverse Stock Split (GlobeNewswire) -18.56%
Nov-14-22 08:45AM	Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-11-22 09:25AM	Palisade Bio Announces Executive Leadership Transition (GlobeNewswire) -12.78%
Sep-29-22 08:35AM	Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 (GlobeNewswire) -6.28%
Sep-23-22 04:30PM	Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.61%
Sep-21-22 09:23AM	Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire)
Sep-15-22 08:30AM	Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148 (GlobeNewswire) -9.15%
Sep-13-22 09:05AM	Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event (GlobeNewswire) +18.33%
Aug-17-22 08:35AM	Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function (GlobeNewswire) -21.41%
Aug-16-22 04:05PM	Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option (GlobeNewswire) -10.99%
Aug-15-22 09:00AM	Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-12-22 08:30AM	Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering (GlobeNewswire) -28.81%
Aug-01-22 08:05AM	Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health (GlobeNewswire)
Jul-27-22 08:05AM	Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function (GlobeNewswire)
Jun-29-22 08:30AM	Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function (GlobeNewswire)
Jun-07-22 08:30AM	Palisade Bio to Present at the 2022 BIO International Convention (GlobeNewswire)
May-13-22 09:00AM	Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.17%
May-10-22 05:00PM	Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires (GlobeNewswire) +11.03%
May-06-22 08:30AM	Palisade Bio Announces $2.0 Million Registered Direct Offering (GlobeNewswire) -27.61%
May-05-22 08:30AM	Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery (GlobeNewswire)
May-02-22 08:35AM	Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements (GlobeNewswire) -5.76%
Apr-29-22 08:05AM	Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event (GlobeNewswire)
Mar-30-22 03:47PM	Companies Like Palisade Bio (NASDAQ:PALI) Could Be Quite Risky (Simply Wall St.)
Mar-24-22 08:30AM	Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-Vest (GlobeNewswire)
Mar-22-22 08:30AM	Palisade Bio (Nasdaq: PALI) Receives FDA Study May Proceed Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery (GlobeNewswire) +30.43%
Mar-18-22 08:30AM	Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update (GlobeNewswire) -11.56%
Mar-16-22 08:00AM	Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93% (GlobeNewswire) -16.10%
Mar-14-22 09:15AM	Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners (Newsfile) -6.97%
Mar-09-22 08:30AM	Palisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting (GlobeNewswire) +10.45%
Feb-18-22 08:30AM	Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference (GlobeNewswire)
Feb-15-22 08:30AM	Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae to Leadership Team (GlobeNewswire)
Feb-08-22 08:00AM	Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting (GlobeNewswire) +8.33%
Dec-29-21 08:30AM	Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase (GlobeNewswire)
Dec-08-21 08:00AM	Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus (GlobeNewswire) +5.26%
Nov-30-21 08:00AM	Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035 (GlobeNewswire)
Nov-23-21 08:00AM	Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations (GlobeNewswire)
Nov-15-21 07:00AM	Palisade Bio Reports Third Quarter Financial Results (GlobeNewswire)
Oct-22-21 08:00AM	Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders (GlobeNewswire) -6.79%
Sep-09-21 08:30AM	Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference (GlobeNewswire) +8.21%

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jones Mitchell Lawrence	CEO, CFO, Director	May 06 '24	Option Exercise	0.00	460	0	880	May 08 06:37 PM
Finley John David	CEO, CFO, Director	May 06 '24	Option Exercise	0.00	443	0	6,832	May 08 06:36 PM
Finley John David	CEO, CFO, Director	Mar 11 '24	Option Exercise	0.00	5,558	0	96,849	Mar 12 06:29 PM
Neal James R	Director	Feb 09 '24	Option Exercise	0.00	10,920	0	10,920	Feb 13 03:08 PM
Trenschel Robert J.	Director	Feb 08 '24	Option Exercise	0.00	10,920	0	10,920	Feb 13 03:08 PM
Csimma Cristina	Director	Feb 08 '24	Option Exercise	0.00	12,800	0	12,862	Feb 13 03:08 PM
Diaz Stephanie	Director	Feb 08 '24	Option Exercise	0.00	12,800	0	12,800	Feb 13 03:08 PM
Finley John David	CEO, CFO, Director	Feb 06 '24	Option Exercise	0.00	6,642	0	91,291	Feb 08 04:37 PM
Jones Mitchell Lawrence	Chief Medical Officer	Feb 06 '24	Option Exercise	0.00	6,891	0	9,815	Feb 08 04:38 PM
Finley John David	CEO, CFO, Director	Feb 06 '24	Buy	0.47	10,000	4,692	84,649	Feb 07 08:30 AM
Williams Donald Allen	Director	Jan 31 '24	Buy	0.60	10,000	6,050	30,000	Feb 01 08:30 AM
Finley John David	CEO, CFO, Director	Jan 31 '24	Buy	0.56	10,000	5,590	74,649	Feb 01 08:30 AM
Finley John David	CEO, CFO, Director	Jan 03 '24	Option Exercise	0.00	1,309	0	64,649	Jan 05 04:00 PM
Finley John David	CEO, CFO, Director	Dec 11 '23	Option Exercise	0.00	5,559	0	63,340	Dec 19 05:57 PM
Finley John David	CEO, CFO, Director	Nov 06 '23	Option Exercise	0.00	3,475	0	47,781	Nov 08 05:01 PM
Jones Mitchell Lawrence	Chief Medical Officer	Nov 06 '23	Option Exercise	0.00	4,556	0	4,556	Nov 08 05:01 PM
Finley John David	CEO, CFO, Director	Oct 03 '23	Option Exercise	0.00	1,309	0	44,703	Oct 05 05:46 PM
Williams Donald Allen	Director	Sep 27 '23	Buy	0.54	20,000	10,800	20,000	Sep 29 09:25 AM
Finley John David	CEO, CFO, Director	Sep 27 '23	Buy	0.54	15,000	8,088	43,394	Sep 29 09:21 AM
Trenschel Robert J.	Director	Sep 14 '23	Sale	0.64	300	192	0	Sep 15 05:15 PM
Finley John David	CEO, CFO, Director	Sep 13 '23	Buy	0.66	15,000	9,825	28,394	Sep 14 05:00 PM
Finley John David	CEO, CFO, Director	Sep 11 '23	Option Exercise	0.00	5,558	0	15,186	Sep 13 04:55 PM
Finley John David	CEO, CFO, Director	Aug 06 '23	Option Exercise	0.00	3,475	0	11,057	Aug 14 06:33 PM
Finley John David	CEO, CFO, Director	Jul 03 '23	Option Exercise	0.00	1,309	0	7,582	Jul 06 06:27 PM
Finley John David	CEO, CFO, Director	Jun 12 '23	Option Exercise	0.00	3,475	0	7,323	Jun 14 06:23 PM

Open in Screener

PCSA

Processa Pharmaceuticals Inc

May 17 • 04:00PM ET

1.96

Dollar change -0.04
Percentage change -2.00	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-6.46	Insider Own	11.94%	Shs Outstand	2.86M	Perf Week	-6.22%
Market Cap	5.61M	Forward P/E	-	EPS next Y	-2.11	Insider Trans	22.62%	Shs Float	2.52M	Perf Month	25.64%
Income	-9.83M	PEG	-	EPS next Q	-1.11	Inst Own	3.72%	Short Float	22.55%	Perf Quarter	-20.97%
Sales	0.00M	P/S	-	EPS this Y	54.86%	Inst Trans	4.99%	Short Ratio	0.38	Perf Half Y	-75.13%
Book/sh	3.11	P/B	0.63	EPS next Y	45.90%	ROA	-87.82%	Short Interest	0.57M	Perf Year	-85.15%
Cash/sh	3.12	P/C	0.63	EPS next 5Y	15.00%	ROE	-103.29%	52W Range	1.40 - 18.00	Perf YTD	-70.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	9.70%	ROI	-109.98%	52W High	-89.11%	Beta	0.56
Dividend TTM	-	Quick Ratio	9.70	Sales past 5Y	0.00%	Gross Margin	-	52W Low	40.00%	ATR (14)	0.23
Dividend Ex-Date	-	Current Ratio	9.70	EPS Y/Y TTM	80.82%	Oper. Margin	0.00%	RSI (14)	44.74	Volatility	7.51% 10.01%
Employees	13	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	44.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	68.71%	Payout	-	Rel Volume	0.02	Prev Close	2.00
Sales Surprise	-	EPS Surprise	1.82%	Sales Q/Q	-	Earnings	-	Avg Volume	1.48M	Price	1.96
SMA20	-6.20%	SMA50	-8.99%	SMA200	-64.70%	Trades		Volume	36,919	Change	-2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-25-24	Initiated	H.C. Wainwright	Buy	$8

May-13-24 10:53AM	PCSA Stock Earnings: Processa Pharma Reported Results for Q1 2024 (InvestorPlace) +6.22%
May-06-24 08:00AM	Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference (GlobeNewswire) +8.29%
Apr-30-24 08:00AM	Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research (GlobeNewswire)
Apr-11-24 08:00AM	Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial (GlobeNewswire)
Mar-28-24 08:15AM	Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference (GlobeNewswire)
08:15AM	Loading…
Mar-25-24 08:15AM	Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Feb-21-24 08:15AM	Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference (GlobeNewswire) -8.47%
Feb-14-24 01:00PM	Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference (GlobeNewswire)
Feb-06-24 08:30AM	Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire)
Feb-01-24 04:22PM	Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering (GlobeNewswire)
Jan-26-24 09:04AM	Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering (GlobeNewswire) -28.04%
Jan-25-24 02:40PM	Why Is Processa Therapeutics (PCSA) Stock Up 90% Today? (InvestorPlace) +148.78%
08:30AM	Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses (GlobeNewswire)
Jan-19-24 07:45AM	Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer (GlobeNewswire) +10.84%
Jan-18-24 07:45AM	Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split (GlobeNewswire) -25.31%
05:06PM	Loading…
Jan-02-24 05:06PM	Processa Pharmaceuticals to Present at the Biotech Showcase 2024 (GlobeNewswire) +5.71%
Dec-19-23 09:00AM	Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine (GlobeNewswire) -21.36%
Dec-13-23 09:00AM	Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine (GlobeNewswire) -25.40%
Nov-30-23 08:15AM	Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference (GlobeNewswire) +20.53%
Nov-29-23 08:15AM	Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook (GlobeNewswire) +17.95%
Nov-13-23 01:40PM	Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson (GlobeNewswire) +20.68%
Nov-09-23 08:15AM	Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas (GlobeNewswire) -6.72%
Nov-01-23 08:15AM	Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders (GlobeNewswire)
Oct-13-23 01:08PM	Processa Pharmaceuticals to Present at the ThinkEquity Conference (GlobeNewswire) +45.41%
Sep-06-23 08:15AM	Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-17-23 08:05AM	Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-10-23 04:15PM	Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference (GlobeNewswire)
Aug-08-23 08:15AM	Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer (GlobeNewswire)
Jun-14-23 04:15PM	Next Generation Chemotherapy: Improved Treatment for More Patients (GlobeNewswire)
08:30AM	Loading…
Jun-13-23 08:30AM	Longeveron Welcomes Three New Prominent Board Members (GlobeNewswire) -5.45%
May-22-23 08:05AM	Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress (GlobeNewswire)
May-18-23 08:00AM	Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative (GlobeNewswire)
Apr-28-23 08:15AM	Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting (GlobeNewswire) +14.46%
Mar-30-23 04:01PM	Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results (GlobeNewswire) +5.63%
Mar-23-23 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST (GlobeNewswire)
Mar-17-23 08:30AM	Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine (GlobeNewswire) +10.64%
Mar-07-23 08:30AM	Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference (GlobeNewswire)
Feb-21-23 08:30AM	Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies (GlobeNewswire)
Feb-15-23 08:30AM	Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules (GlobeNewswire)
Feb-10-23 08:00AM	Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules (GlobeNewswire)
Jan-04-23 08:30AM	Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023. (GlobeNewswire)
Dec-14-22 08:30AM	Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial (GlobeNewswire)
Nov-08-22 04:00PM	Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
08:30AM	PCS12852 Improves Gastric Emptying in Gastroparesis Patients (GlobeNewswire)
Nov-02-22 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST (GlobeNewswire) -6.38%
Nov-01-22 08:30AM	Processa Successfully Identifies Next Generation Capecitabine Dosage Regimens for Phase 2B Trial (GlobeNewswire) +7.75%
Sep-15-22 08:30AM	Processa Pharmaceuticals Provides Update on Enrollment Across all Clinical Programs (GlobeNewswire)
Sep-07-22 08:30AM	Processa Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 12-14, 2022 (GlobeNewswire)
Aug-16-22 08:30AM	Processa Pharmaceuticals Appoints Khoso Baluch and James Neal to its Board of Directors and Justin Yorke to Chairman of the Board (GlobeNewswire)
Aug-12-22 09:30AM	Processa Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-05-22 03:00PM	Processa Pharmaceuticals to Host Conference Call to Discuss Its Second Quarter 2022 Results and Provide 2nd Half Clinical Pipeline Update on August 11, 2022, at 4:30 p.m. EST (GlobeNewswire)
Aug-04-22 09:30AM	Processa Pharmaceuticals Announces Launch of Website to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 (GlobeNewswire)
Aug-03-22 04:00PM	Processa Pharmaceuticals Announces Launch of Website (www.Necrobiosislipoidicastudy.com) to Increase Awareness of Ulcerative Necrobiosis Lipoidica and to Inform Patients of the ongoing Phase 2B Study of PCS499 (GlobeNewswire)
Jul-12-22 08:30AM	Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, July 11-13, 2022 (GlobeNewswire)
Jun-24-22 09:06AM	Here's Why We're Watching Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Situation (Simply Wall St.) +5.21%
May-12-22 04:20PM	Processa Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +8.94%
May-05-22 08:30AM	Processa Pharmaceuticals to Host Conference Call to Discuss First Quarter 2022 Results and Provide Drug Development Update on May 12, 2022 at 4:30 p.m. EST (GlobeNewswire)
Apr-20-22 08:30AM	Processa Pharmaceuticals Doses First Patient in Amended Phase 1B Protocol for PCS6422 Combined with Capecitabine (Next Generation Capecitabine) (GlobeNewswire)
Apr-05-22 08:30AM	Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis (GlobeNewswire)
Mar-30-22 04:00PM	Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update (GlobeNewswire)
Mar-23-22 08:30AM	Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST (GlobeNewswire)
Mar-10-22 08:30AM	Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire)
Jan-26-22 08:15AM	Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022 (GlobeNewswire)
Jan-17-22 08:42AM	Multiple insiders bought Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) stock earlier this year, a positive sign for shareholders (Simply Wall St.)
Nov-11-21 04:05PM	Processa Pharmaceuticals Announces Third Quarter 2021 Results and Provides Corporate Update (GlobeNewswire)
Nov-04-21 08:15AM	Processa Pharmaceuticals Announces Next Generation Capecitabine (Combination of PCS6422 and Capecitabine) Inhibits DPD in Phase 1b Interim Analysis (GlobeNewswire)
Oct-26-21 08:30AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Third Quarter Results and Provide Drug Development Update on November 11 at 5:30 p.m. EST (GlobeNewswire)
Oct-19-21 10:22AM	What Kind Of Shareholders Hold The Majority In Processa Pharmaceuticals, Inc.'s (NASDAQ:PCSA) Shares? (Simply Wall St.) -6.74%
Oct-12-21 08:30AM	Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis (GlobeNewswire)
Sep-16-21 11:05AM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Update (GlobeNewswire) +5.52%
08:30AM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-23-21 04:00PM	Processa Pharmaceuticals to Present at the World Orphan Drug Congress USA, August 25-27 (GlobeNewswire) +5.89%
Aug-20-21 10:54AM	Companies Like Processa Pharmaceuticals (NASDAQ:PCSA) Are In A Position To Invest In Growth (Simply Wall St.)
Aug-12-21 05:15PM	Processa Pharmaceuticals Announces Second Quarter 2021 Results and Provides Corporate Update (GlobeNewswire)
Aug-06-21 08:30AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Second Quarter Results and Provide Drug Development Update on August 12 at 5:30 p.m. EST (GlobeNewswire)
Aug-05-21 09:51AM	Buy These 3 Stocks Before They Double (or More), Say Analysts (TipRanks) +7.83%
Aug-04-21 08:30AM	Processa Announces First Patient Dosed in PCS6422 Study in Gastrointestinal Cancer (GlobeNewswire)
Jul-27-21 08:30AM	Processa Pharmaceuticals to Present at Zooming with LD Micro Virtual Investor Event on July 29, 2021 at 12:00 p.m. ET (GlobeNewswire) -6.75%
Jul-08-21 11:20AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
Jul-06-21 08:15AM	Processa Pharmaceuticals to Present at Access to Giving Virtual Conference on July 14, 2021 at 10:30 a.m. ET (GlobeNewswire)
Jun-23-21 09:35AM	50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 (ACCESSWIRE)
Jun-17-21 09:15AM	PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117 (GlobeNewswire)
Jun-08-21 09:15AM	Processa Set to Join Russell Microcap® Index (GlobeNewswire)
Jun-07-21 04:05PM	Processa Pharmaceuticals to Present at LD Micro Virtual Investor Conference on June 9, 2021, at 1:30pm ET (GlobeNewswire)
May-26-21 09:15AM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-20-21 04:05PM	Processa Pharmaceuticals Announces First Patient Dosed in its Randomized Double-Blind, Placebo-Controlled Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Have Necrobiosis Lipoidica (GlobeNewswire) +5.54%
04:15AM	Read This Before Selling Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares (Simply Wall St.)
May-18-21 04:05PM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.11%
May-13-21 04:55PM	Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update (GlobeNewswire)
May-07-21 08:30AM	Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on May 13 at 5:30 p.m. EST (GlobeNewswire)
Mar-25-21 04:06PM	Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update (GlobeNewswire)
Mar-22-21 09:15AM	Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET (GlobeNewswire)
Mar-17-21 09:15AM	Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica (GlobeNewswire)
Mar-02-21 09:15AM	Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement (GlobeNewswire)
Feb-22-21 08:30AM	Encode Ideas, L.P. Announces the Initiation of Research Coverage on Processa Pharmaceuticals, Inc. (Newsfile) +6.80%
Feb-19-21 05:16AM	Do Institutions Own Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares? (Simply Wall St.)
Feb-17-21 08:00AM	Processa Pharmaceuticals Announces $10.2 Million Strategic Financing (GlobeNewswire) +33.17%
Jan-11-21 10:50AM	Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference (GlobeNewswire)
Nov-16-20 12:48PM	Processa Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.39%

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Hanover, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Young David	Pres. Research & Development	Feb 07 '24	Buy	2.45	21,000	51,526	79,387	Feb 08 04:30 PM
Young David	Pres. Research & Development	Feb 06 '24	Buy	2.53	20,000	50,504	58,387	Feb 07 04:22 PM
Lin Patrick	Chief Business - Strategy Off	Feb 01 '24	Buy	2.40	1,500	3,600	27,478	Feb 01 06:32 PM
Lin Patrick	Chief Business - Strategy Off	Jan 31 '24	Buy	2.37	2,500	5,925	25,978	Feb 01 06:32 PM
Ng George K	Chief Executive Officer	Jan 30 '24	Buy	2.70	10,000	27,000	20,000	Jan 31 04:37 PM
Yorke Justin W	Director	Jan 30 '24	Buy	2.69	8,000	21,544	31,232	Jan 31 04:34 PM
Young David	President & CEO	Jun 12 '23	Buy	0.80	40,000	32,000	470,424	Jun 12 04:31 PM

Open in Screener

XOMA

XOMA Corp

May 17 • 04:00PM ET

25.51

Dollar change -0.15
Percentage change -0.58	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWC VTWV RYLD AVSC DFAC

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	0.40%	Shs Outstand	11.64M	Perf Week	0.28%
Market Cap	296.94M	Forward P/E	-	EPS next Y	-1.40	Insider Trans	0.00%	Shs Float	11.59M	Perf Month	3.74%
Income	-45.09M	PEG	-	EPS next Q	-0.43	Inst Own	65.84%	Short Float	2.34%	Perf Quarter	10.29%
Sales	5.81M	P/S	51.11	EPS this Y	50.33%	Inst Trans	0.91%	Short Ratio	16.71	Perf Half Y	60.84%
Book/sh	7.07	P/B	3.61	EPS next Y	30.40%	ROA	-22.44%	Short Interest	0.27M	Perf Year	19.26%
Cash/sh	11.75	P/C	2.17	EPS next 5Y	19.00%	ROE	-40.24%	52W Range	13.48 - 27.00	Perf YTD	37.89%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-20.43%	ROI	-22.86%	52W High	-5.52%	Beta	0.85
Dividend TTM	-	Quick Ratio	9.45	Sales past 5Y	46.25%	Gross Margin	87.51%	52W Low	89.24%	ATR (14)	1.11
Dividend Ex-Date	-	Current Ratio	9.45	EPS Y/Y TTM	-49.10%	Oper. Margin	-393.29%	RSI (14)	52.44	Volatility	4.14% 4.15%
Employees	13	Debt/Eq	1.47	Sales Y/Y TTM	73.10%	Profit Margin	-775.86%	Recom	1.67	Target Price	58.00
Option/Short	Yes / Yes	LT Debt/Eq	1.39	EPS Q/Q	11.81%	Payout	-	Rel Volume	0.45	Prev Close	25.66
Sales Surprise	11.47%	EPS Surprise	-21.13%	Sales Q/Q	240.96%	Earnings	May 09 BMO	Avg Volume	16.24K	Price	25.51
SMA20	0.77%	SMA50	1.28%	SMA200	30.44%	Trades		Volume	7,231	Change	-0.58%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-24	Initiated	Leerink Partners	Outperform	$40
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral	$22
Jun-29-21	Initiated	Aegis Capital	Buy	$60
Jan-19-21	Reiterated	H.C. Wainwright	Buy	$30 → $56
Jan-18-18	Reiterated	H.C. Wainwright	Buy	$38 → $49
Oct-17-17	Resumed	H.C. Wainwright	Buy	$38
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform	$9 → $19
Jun-12-17	Initiated	H.C. Wainwright	Buy	$15
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral	$17 → $14
Mar-11-16	Reiterated	Wedbush	Outperform	$6 → $3
Jul-23-15	Downgrade	Jefferies	Buy → Hold
Jul-22-15	Downgrade	Piper Jaffray	Overweight → Neutral
Jul-22-15	Downgrade	Ladenburg Thalmann	Buy → Neutral
Oct-10-14	Resumed	ROTH Capital	Buy	$9
Apr-29-14	Upgrade	MLV & Co	Hold → Buy	$7
Mar-11-14	Downgrade	MLV & Co	Buy → Hold	$8 → $7
Mar-05-14	Reiterated	Ladenburg Thalmann	Buy	$6.50 → $10
Oct-31-13	Reiterated	MLV & Co	Buy	$7.50 → $8
May-09-13	Reiterated	Ladenburg Thalmann	Buy	$5 → $6
May-14-12	Initiated	Cowen & Co	Outperform

Show Previous Ratings

May-14-24 07:30AM	XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ (GlobeNewswire)
May-10-24 03:18PM	XOMA Corp (XOMA) Q1 2024 Earnings: Misses Revenue Estimates, Reports Lower Net Loss (GuruFocus.com) +7.39%
May-09-24 01:55PM	XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00AM	Xoma: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities (GlobeNewswire)
10:00AM	Loading…
May-07-24 10:00AM	Xoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
Apr-30-24 07:30AM	XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO (clindamycin phosphate) Vaginal Gel 2% (GlobeNewswire)
Apr-25-24 07:30AM	XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire)
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-03-24 09:00AM	XOMA Corporation Announces Closing of Tender Offer (GlobeNewswire)
Mar-21-24 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-19-24 04:05PM	XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc. (GlobeNewswire)
Mar-08-24 12:53PM	XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
08:12AM	XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
07:52AM	Xoma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value (GlobeNewswire)
Feb-28-24 07:30AM	XOMA to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-16-24 08:00AM	XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (GlobeNewswire)
Jan-18-24 08:30AM	XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA Acquisition (GlobeNewswire)
Jan-11-24 04:05PM	FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx (GlobeNewswire)
Jan-08-24 07:30AM	XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors (GlobeNewswire)
Jan-02-24 07:30AM	XOMA Announces Stock Repurchase Program of up to $50 Million (GlobeNewswire) +12.92%
Dec-20-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-19-23 07:30AM	XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO Royalties (GlobeNewswire) +16.23%
Nov-07-23 07:50AM	Xoma: Q3 Earnings Snapshot (Associated Press Finance) -6.44%
07:30AM	XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value (GlobeNewswire)
Oct-31-23 07:30AM	XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One's Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) (GlobeNewswire) +5.66%
Sep-25-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) -6.26%
Sep-06-23 07:30AM	XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 10:43PM	10 Stocks That Are About To Explode (Insider Monkey)
10:07AM	Loading…
Aug-13-23 10:07AM	Owning 35% shares,institutional owners seem interested in XOMA Corporation (NASDAQ:XOMA), (Simply Wall St.)
Aug-08-23 08:21AM	Xoma: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy (GlobeNewswire)
Jun-23-23 06:14PM	XOMA Added to the Russell 2000® and Russell 3000® Indexes (GlobeNewswire)
Jun-22-23 07:30AM	XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset (GlobeNewswire)
Jun-20-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) +9.30%
May-16-23 09:29AM	Shareholders in XOMA (NASDAQ:XOMA) are in the red if they invested five years ago (Simply Wall St.)
May-09-23 07:53AM	Xoma: Q1 Earnings Snapshot (AP Finance)
07:30AM	XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy (GlobeNewswire)
Apr-26-23 07:30AM	XOMA to Present at H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) +5.61%
Mar-30-23 07:30AM	XOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone Portfolio (GlobeNewswire)
Mar-21-23 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-10-23 05:36AM	XOMA Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.)
Mar-09-23 07:50AM	Xoma: Q4 Earnings Snapshot (AP Finance) +5.76%
07:30AM	XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy (GlobeNewswire)
Mar-06-23 08:28AM	XOMA Corporation's (NASDAQ:XOMA) largest shareholders are individual investors with 37% ownership, hedge funds own 32% (Simply Wall St.)
Feb-28-23 07:30AM	XOMA to Present at 43rd Annual Cowen Health Care Conference (GlobeNewswire)
Jan-06-23 07:00PM	XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-04-23 07:30AM	New Executive Leadership Team Appointed to Accelerate XOMAs Differentiated Royalty Monetization Strategy (GlobeNewswire)
Dec-22-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-07-22 07:44AM	XOMA (NASDAQ:XOMA) shareholders have endured a 39% loss from investing in the stock five years ago (Simply Wall St.)
Nov-22-22 07:01AM	XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon (GlobeNewswire) +15.91%
Nov-06-22 09:24AM	XOMA Corporation's (NASDAQ:XOMA) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong? (Simply Wall St.)
Nov-03-22 09:05AM	Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:30AM	XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events (GlobeNewswire)
Sep-27-22 08:30AM	Hedge funds own 31% of XOMA Corporation (NASDAQ:XOMA) shares but individual investors control 40% of the company (Simply Wall St.)
Sep-21-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Sep-07-22 07:30AM	XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-01-22 06:20AM	Is There An Opportunity With XOMA Corporation's (NASDAQ:XOMA) 49% Undervaluation? (Simply Wall St.) -7.34%
Aug-11-22 06:22AM	Time To Worry? Analysts Are Downgrading Their XOMA Corporation (NASDAQ:XOMA) Outlook (Simply Wall St.)
Aug-04-22 10:45AM	Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -6.64%
07:30AM	XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events (GlobeNewswire)
Jun-30-22 07:33AM	Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 196% gain (Simply Wall St.) +8.95%
Jun-20-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Jun-02-22 01:00AM	Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment (GlobeNewswire)
May-30-22 07:06AM	Is Weakness In XOMA Corporation (NASDAQ:XOMA) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? (Simply Wall St.)
May-17-22 04:05PM	XOMA to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire)
May-07-22 08:27AM	This Just In: Analysts Are Boosting Their XOMA Corporation (NASDAQ:XOMA) Outlook for This Year (Simply Wall St.)
May-05-22 08:55AM	Xoma (XOMA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:30AM	XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events (GlobeNewswire)
May-03-22 08:15AM	Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
Apr-20-22 08:24AM	What Is The Ownership Structure Like For XOMA Corporation (NASDAQ:XOMA)? (Simply Wall St.)
Mar-21-22 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Mar-15-22 06:21AM	XOMA Corporation's (NASDAQ:XOMA) 32% Share Price Surge Not Quite Adding Up (Simply Wall St.)
Mar-10-22 09:43AM	XOMA Corporation (NASDAQ:XOMA) Shares Could Be 20% Below Their Intrinsic Value Estimate (Simply Wall St.)
07:30AM	XOMA to Present at Oppenheimers 32nd Annual Healthcare Conference (GlobeNewswire)
Mar-08-22 07:30AM	XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events (GlobeNewswire) +11.47%
Mar-01-22 07:30AM	XOMA to Present at the 42nd Annual Cowen Health Care Conference (GlobeNewswire)
Feb-17-22 07:30AM	XOMA to Present at Aegis Capital Corp Investor Conference (GlobeNewswire)
Jan-21-22 10:21AM	XOMA's (NASDAQ:XOMA) investors will be pleased with their massive 368% return over the last five years (Simply Wall St.)
Dec-23-21 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire)
Dec-21-21 07:30AM	XOMA to Present at Upcoming Investor Conferences (GlobeNewswire) +7.94%
Dec-16-21 07:30AM	XOMA Announces Evolution of Company Leadership and Succession Planning (GlobeNewswire)
Nov-22-21 11:46AM	Should Weakness in XOMA Corporation's (NASDAQ:XOMA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? (Simply Wall St.)
Nov-15-21 06:01AM	10 Best Biotech Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey)
Nov-04-21 10:15AM	Xoma (XOMA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:40AM	XOMA Earns $35 Million Milestone Payment as Anti-TGF Antibody Enters Phase 3 Clinical Study in Metastatic Pancreatic Cancer (GlobeNewswire)
07:30AM	XOMA Reports Third Quarter 2021 Financial Results and Highlights Recent Operational Events (GlobeNewswire)
Oct-28-21 03:06PM	Will Xoma (XOMA) Report Negative Q3 Earnings? What You Should Know (Zacks)
Oct-27-21 04:50AM	10 Pharma Stocks to Buy According to Mark Lamperts Biotechnology Value Fund (Insider Monkey)
Oct-14-21 06:57AM	10 Pharmaceutical Stocks to Buy According to Timothy Lynchs Stonepine Capital (Insider Monkey)
Oct-08-21 03:35AM	Strength Seen in Xoma (XOMA): Can Its 11.2% Jump Turn into More Strength? (Zacks) +8.96%
Sep-22-21 07:30AM	XOMA to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference (GlobeNewswire)
Sep-21-21 12:33PM	Here's What XOMA Corporation's (NASDAQ:XOMA) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Sep-20-21 07:30AM	XOMA Declares Quarterly Preferred Stock Dividends (GlobeNewswire) -6.94%
Sep-13-21 07:30AM	XOMA to Present at H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-07-21 01:49PM	Why Did Wedbush Downgrade Xoma? (Benzinga) -12.53%
Aug-10-21 04:35PM	XOMA Announces Heather L. Franklin Joins its Board of Directors (GlobeNewswire)
Aug-05-21 08:45AM	Xoma (XOMA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	XOMA Reports Second Quarter 2021 Financial Results and Highlights Recent Operational Events (GlobeNewswire)

XOMA Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets that provides right to future potential royalty and milestone payments. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sitko Bradley	Chief Investment Officer	Oct 03 '23	Buy	13.89	250	3,472	5,600	Oct 04 04:30 PM
Sitko Bradley	Chief Investment Officer	Oct 02 '23	Buy	14.25	1,500	21,375	5,350	Oct 04 04:30 PM
Hughes Owen	Exec Chairman and Interim CEO	Oct 02 '23	Buy	13.83	1,000	13,830	3,500	Oct 04 04:30 PM
Hughes Owen	Exec Chairman and Interim CEO	Sep 26 '23	Buy	14.43	2,499	36,061	2,500	Sep 27 04:30 PM
Hughes Owen	Exec Chairman and Interim CEO	Sep 25 '23	Buy	14.65	1	15	1	Sep 27 04:30 PM
Sitko Bradley	Chief Investment Officer	May 31 '23	Buy	17.13	1,500	25,700	3,500	Jun 02 04:30 PM
Hughes Owen	Interim CEO	May 24 '23	Buy	23.79	1,032	24,551	2,000	May 25 04:30 PM
Hughes Owen	Interim CEO	May 23 '23	Buy	23.46	968	22,706	968	May 25 04:30 PM
Sitko Bradley	Chief Investment Officer	May 23 '23	Buy	19.00	850	16,150	3,850	May 25 04:30 PM
Sitko Bradley	Chief Investment Officer	May 19 '23	Buy	19.50	1,000	19,500	3,000	May 22 04:30 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PALI

Palisade Bio Inc

PCSA

Processa Pharmaceuticals Inc

XOMA

XOMA Corp

Upgrade your FINVIZ experience